Breast cancer is the leading type of cancer diagnosed in women worldwide and requires predictive research models during the preclinical phase of drug development.
Patient-derived xenograft (PDX) models provide a true representation of human heterogeneity and can be used to test the efficacy of novel compounds against drug resistance.
Our breast cancer PDX models offer the most translational preclinical models for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, patient-derived xenografts reflect the heterogeneity and diversity of the human patient population. PDX models give you an accurate, predictive model of how your compound will perform before entering clinical trials. Crown Bioscience’s breast cancer PDX model collection, known as HuPrime®, is well characterized for pathology, growth characteristics, and are also genetically and genomically annotated for gene expression, gene copy number, mutations, and fusions.
Explore our new breast cancer PDX models, which include pretreated and/or metastatic breast tumors that exhibit therapy resistance, and models with clinically relevant mutations in BRCA1 and ESR1 genes.
Our breast cancer PDX collection consists of a wide range of models, including triple negative breast cancer (TNBC) models as well as ER+, PR+, and HER2+ models. Breast cancer organoids are also available to complement our PDX in vivo collection.